Table 5.
Final population pharmacokinetic estimates and bootstrap results for azithromycin in pregnant Papua New Guinean women
| Parameter | Mean | RSE% | Bootstrap median [95% CI ] |
|---|---|---|---|
| Objective function value | −122.715 | −133.692 [−201.308, –73.288] | |
| Structural model parameters | |||
| k a ( h −1 ) | 0.89 | 12 | 0.92 [0.64, 1.44] |
| DUR (h) | 1.67 | 4 | 1.65 [0.98, 2.06] |
| CL/F AZI ( l h −1 70 kg −1 ) | 76.0 | 5 | 75.7 [67.6, 84.5] |
| V C /F AZI ( l h −1 70 kg −1 ) | 365 | 25 | 393 [198, 859] |
| Q 1 /F AZI ( l h −1 70 kg −1 ) | 228 | 14 | 223 [151, 297] |
| V P1 /F AZI ( l h −1 70 kg −1 ) | 2670 | 20 | 2660 [1457, 3883] |
| Q 2 /F AZI ( l h −1 70 kg −1 ) | 59 | 23 | 58.0 [32.9, 93.4] |
| V P2 /F AZI ( l h −1 70 kg −1 ) | 3980 | 13 | 3940 [2809, 4943] |
| Variable model parameters [shrinkage %] | |||
| IIV in DUR (%) | 60 [45] | 23 | 57 [9, 116] |
| IIV in CL/F AZI (%) | 25 [8] | 10 | 24 [13, 33] |
| IIV in V C /F AZI (%) | 127 [12] | 18 | 119 [51, 179] |
| r(CL/F AZI ,V P1 /F AZI ) | −0.80 | 10 | −0.86 [−1.00, –0.11] |
| RV for AZI (%) | 33 [12] | 10 | 29 [27, 32] |
CI, confidence interval; CL/FAZI, clearance relative to bioavailability; DUR, duration of zero‐order absorption; ka, rate for first‐order absorption; IIV, interindividual variability; Q1/FAZI, intercompartmental clearance for VP1/FAZI; Q2/FAZI, intercompartmental clearance for VP2/FAZI; RSE, residual standard error; RV, residual variability; VC/FAZI, central volume of distribution relative to bioavailability; VP1/FAZI, first peripheral volume of distribution relative to bioavailability; VP2/FAZI, second peripheral volume of distribution relative to bioavailability. IIV is presented as 100% × √(variability estimate).